Immunopathogenesis of Neuromyelitis Optica

Advances in Immunology

Volumn 121, Issue , 2014, Pages 213-242

  Levy, Michael ^a   Wildemann, Brigitte ^c   Jarius, Sven ^c   Orellano, Benjamine ^b   Sasidharan, Saranya ^a   Weber, Martin S ^d   Stuve, Olaf ^b,e,f,g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aquaporin 4; Immunopathogenesis; Neuromyelitis optica; NMO IgG

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AQUAPORUMAB; ECULIZUMAB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; T LYMPHOCYTE;

AQUAPORIN-4; IMMUNOPATHOGENESIS; NEUROMYELITIS OPTICA; NMO-IGG;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AQUAPORIN 4; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; HUMANS; IMMUNITY, INNATE; NEUROMYELITIS OPTICA; T-LYMPHOCYTE SUBSETS;

EID: 84891353177     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800100-4.00006-4     Document Type: Chapter

References (144)

1. Akman-Demir G., Tuzun E., Waters P., Icoz S., Kurtuncu M., Jarius S., et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology 2011, 258:464-470.
2. Apiwattanakul M., Popescu B.F., Matiello M., Weinshenker B.G., Lucchinetti C.F., Lennon V.A., et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Annals of Neurology 2010, 68:757-761.
3. Araki M., Aranami T., Matsuoka T., Nakamura M., Miyake S., Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern Rheumatology 2012, 23:827-831.
4. Arellano B., Hussain R., Zacharias T., Yoon J., David C., Zein S., et al. Human Aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: Relevance for diagnosing and monitoring patients with Neuromyelitis Optica. Archives of Neurology 2012, 69:1125-1131.
5. Ayzenberg I., Kleiter I., Schroder A., Hellwig K., Chan A., Yamamura T., et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurology 2013, 70:394-397.
6. Barnett M.H., Parratt J.D., Cho E.S., Prineas J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of Neurology 2009, 65:32-46.
7. Barnett M.H., Prineas J.W., Buckland M.E., Parratt J.D., Pollard J.D. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Multiple Sclerosis 2012, 18:108-112.
8. Bedi G.S., Brown A.D., Delgado S.R., Usmani N., Lam B.L., Sheremata W.A. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Multiple Sclerosis 2011, 17:1225-1230.
9. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Annals of Neurology 2009, 66:617-629.
10. Bonnan M., Valentino R., Olindo S., Mehdaoui H., Smadja D., Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Multiple Sclerosis 2009, 15:487-492.
11. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Annals of Neurology 2009, 66:630-643.
12. Brum D.G., Barreira A.A., dos Santos A.C., Kaimen-Maciel D.R., Matiello M., Costa R.M., et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Multiple Sclerosis 2010, 16:21-29.
13. Chihara N., Aranami T., Sato W., Miyazaki Y., Miyake S., Okamoto T., et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:3701-3706.
14. Clinicaltrials.gov webpage: http://www.clinicaltrials.gov/ct2/show/NCT01759602.
15. Cocks B.G., de Waal M.R., Galizzi J.P., de Vries J.E., Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. International Immunology 1993, 5:657-663.
16. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nature Immunology 2011, 12:560-567.
17. Constant S., Sant'Angelo D., Pasqualini T., Taylor T., Levin D., Flavell R., et al. Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. Journal of Immunology 1995, 154:4915-4923.
18. Constant S., Schweitzer N., West J., Ranney P., Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. Journal of Immunology 1995, 155:3734-3741.
19. Crane J.M., Lam C., Rossi A., Gupta T., Bennett J.L., Verkman A.S. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. The Journal of Biological Chemistry 2011, 286:16516-16524.
20. Cravens P.D., Hussain R.Z., Zacharias T.E., Ben L.H., Herndon E., Vinnakota R., et al. Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. Journal of Neuroinflammation 2011, 8:73.
21. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
22. Doi H., Matsushita T., Isobe N., Matsuoka T., Minohara M., Ochi H., et al. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Multiple Sclerosis 2009, 15:304-310.
23. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nature Immunology 2011, 12:568-575.
24. Fujinami R.S., Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science 1985, 230:1043-1045.
25. Geluk A., Fu X.T., van Meijgaarden K.E., Jansen Y.Y., De Vries R.R., Karr R.W., et al. T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain. European Journal of Immunology 1994, 24:3241-3244.
26. Ghezzi A., Bergamaschi R., Martinelli V., Trojano M., Tola M.R., Merelli E., et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. Journal of Neurology 2004, 251:47-52.
27. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. Journal of Immunology 2009, 183:3170-3176.
28. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005, 6:1123-1132.
29. Hedberg H. Depression of synovial fluid complement activity and rheumatoid factor positivity. Acta Medica Scandinavica 1970, 188:409-413.
30. Hinson S.R., McKeon A., Fryer J.P., Apiwattanakul M., Lennon V.A., Pittock S.J. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Archives of Neurology 2009, 66:1164-1167.
31. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., Kryzer T.J., et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
32. Hinson S.R., Roemer S.F., Lucchinetti C.F., Fryer J.P., Kryzer T.J., Chamberlain J.L., et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. The Journal of Experimental Medicine 2008, 205:2473-2481.
33. Hinson S.R., Romero M.F., Popescu B.F., Lucchinetti C.F., Fryer J.P., Wolburg H., et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1245-1250.
34. Huppke P., Bluthner M., Bauer O., Stark W., Reinhardt K., Huppke B., et al. Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 2010, 75:1740-1744.
35. Iorio R., Fryer J.P., Hinson S.R., Fallier-Becker P., Wolburg H., Pittock S.J., et al. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. Journal of Autoimmunity 2012, 40:21-27.
36. Iorio R., Lucchinetti C.F., Lennon V.A., Farrugia G., Pasricha P.J., Weinshenker B.G., et al. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clinical Gastroenterology and Hepatology 2013, 11:240-245.
37. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
38. Isobe N., Yonekawa T., Matsushita T., Kawano Y., Masaki K., Yoshimura S., et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Multiple Sclerosis 2012, 18:1541-1551.
39. Jacob A., Saadoun S., Kitley J., Leite M.I., Palace J., Schon F., et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: Clinical case and histological evidence. Multiple Sclerosis 2012, 18:1801-1803.
40. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., Fox R.J., et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Archives of Neurology 2008, 65:1443-1448.
41. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
42. Jarius S., Franciotta D., Bergamaschi R., Wildemann B., Wandinger K.P. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clinical Chemistry and Laboratory Medicine 2010, 48:659-663.
43. Jarius S., Franciotta D., Bergamaschi R., Wright H., Littleton E., Palace J., et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
44. Jarius S., Franciotta D., Paul F., Bergamaschi R., Rommer P.S., Ruprecht K., et al. Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. Journal of the Neurological Sciences 2012, 320:32-37.
45. Jarius S., Franciotta D., Paul F., Ruprecht K., Bergamaschi R., Rommer P.S., et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance. Journal of Neuroinflammation 2010, 7:52.
46. Jarius S., Frederikson J., Waters P., Paul F., Akman-Demir G., Marignier R., et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences 2010, 298:158-162.
47. Jarius S., Jacob S., Leite M.I., Waters P., Vincent A. NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro. Multiple Sclerosis 2007, 13:P533.
48. Jarius S., Paul F., Franciotta D., de Seze J., Munch C., Salvetti M., et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: Ten new aquaporin-4 antibody positive cases and a review of the literature. Multiple Sclerosis 2012, 18:1135-1143.
49. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., et al. Mechanisms of Disease: Aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice. Neurology 2008, 4:202-214.
50. Jarius S., Ruprecht K., Wildemann B., Kuempfel T., Ringelstein M., Geis C., et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation 2012, 9:14.
51. Jarius S., Wildemann B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nature Reviews. Neurology 2010, 6:383-392.
52. Jarius S., Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathology 2013, 23:661-683.
53. Kalluri S.R., Illes Z., Srivastava R., Cree B., Menge T., Bennett J.L., et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Archives of Neurology 2010, 67:1201-1208.
54. Kalluri S.R., Rothhammer V., Staszewski O., Srivastava R., Petermann F., Prinz M., et al. Functional characterization of aquaporin-4 specific T cells: Towards a model for neuromyelitis optica. PLoS One 2011, 6:e16083.
55. Khatri B.O., Kramer J., Dukic M., Palencia M., Verre W. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. Journal of Clinical Apheresis 2012, 27:183-192.
56. Kieseier B.C., Stuve O., Dehmel T., Goebels N., Leussink V.I., Mausberg A.K., et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: Implication for cellular immune responses. Archives of Neurology 2012, 70:390-393.
57. Kim S.H., Kim W., Huh S.Y., Lee K.Y., Jung I.J., Kim H.J. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. The Journal of Clinical Neurology 2013, 9:36-42.
58. Kim S.H., Kim W., Li X.F., Jung I.J., Kim H.J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Archives of Neurology 2011, 68:1412-1420.
59. Kim W., Lee J.E., Li X.F., Kim S.H., Han B.G., Lee B.I., et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Multiple Sclerosis 2012, 18:578-586.
60. King I.L., Dickendesher T.L., Segal B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113:3190-3197.
61. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochemical and Biophysical Research Communications 2009, 386:623-627.
62. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochemical and Biophysical Research Communications 2010, 394:205-210.
63. Kitley J., Leite M.I., Nakashima I., Waters P., McNeillis B., Brown R., et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012, 135:1834-1849.
64. Kleiter I., Hellwig K., Berthele A., Kumpfel T., Linker R.A., Hartung H.P., et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Archives of Neurology 2012, 69:239-245.
65. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:18460-18465.
66. Kowarik M.C., Cepok S., Sellner J., Grummel V., Weber M.S., Korn T., et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. Journal of Neuroinflammation 2012, 9:93.
67. Kuroda H., Fujihara K., Takano R., Takai Y., Takahashi T., Misu T., et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. Journal of Neuroimmunology 2012, 254:178-182.
68. Laino C. NEWS FROM THE AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETING: Eculizumab shows promise for preventing NMO attacks, keeping disease in check. Neurology Today 2012, 12(1):25-27.
69. Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
70. Leite M.I., Coutinho E., Lana-Peixoto M., Apostolos S., Waters P., Sato D., et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology 2012, 78:1601-1607.
71. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. The Journal of Experimental Medicine 2005, 202:473-477.
72. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
73. Linhares U.C., Schiavoni P.B., Barros P.O., Kasahara T.M., Teixeira B., Ferreira T.B., et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. Journal of Clinical Immunology 2013, 33:179-189.
74. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
75. Mader S., Lutterotti A., Di Pauli F., Kuenz B., Schanda K., Aboul-Enein F., et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 2010, 5:e10455.
76. Matiello M. NMO-IgG predicts the outcome of recurrent optic neuritis. Multiple Sclerosis 2007, 13(Suppl 2):P536.
77. Matiello M., Sun D., Schaefer-Klein J., Weinshenker B. Tissue susceptibility to neuromyelitis optica is associated with aquaporin-4 expression and supramolecular aggregation. JAMA Neurology 2012, 70:1118-1125.
78. Melamud L., Fernandez J.M., Rivarola V., Di Giusto G., Ford P., Villa A., et al. Neuromyelitis optica immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane. Journal of Neuroscience Research 2012, 90:1240-1248.
79. Merle H., Olindo S., Jeannin S., Valentino R., Mehdaoui H., Cabot F., et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Archives of Ophthalmology 2012, 130:858-862.
80. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
81. Misu T., Fujihara K., Nakamura M., Murakami K., Endo M., Konno H., et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: A case report. The Tohoku Journal of Experimental Medicine 2006, 209:269-275.
82. Mitsdoerffer M., Lee Y., Jager A., Kim H.J., Korn T., Kolls J.K., et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14292-14297.
83. Miyamoto M., Prause O., Sjostrand M., Laan M., Lotvall J., Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. Journal of Immunology 2003, 170:4665-4672.
84. Molina H. Update on complement in the pathogenesis of systemic lupus erythematosus. Current Opinion in Rheumatology 2002, 14:492-497.
85. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. Journal of Immunology 1986, 136:2348-2357.
86. Nelson P.A., Khodadoust M., Prodhomme T., Spencer C., Patarroyo J.C., Varrin-Doyer M., et al. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 2010, 5:e15050.
87. Nicchia G.P., Mastrototaro M., Rossi A., Pisani F., Tortorella C., Ruggieri M., et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57:1363-1373.
88. Nishiyama S., Ito T., Misu T., Takahashi T., Kikuchi A., Suzuki N., et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009, 72:1960-1961.
89. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
90. Papadopoulos M.C., Verkman A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurology 2012, 11:535-544.
91. Patel V., Griffith N.C., Blackwood E., Dias M., Cordato D.J. Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. Journal of Clinical Neuroscience 2012, 19:1576-1578.
92. Pellkofer H.L., Krumbholz M., Berthele A., Hemmer B., Gerdes L.A., Havla J., et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011, 76:1310-1315.
93. Phuan P.W., Anderson M.O., Tradtrantip L., Zhang H., Tan J., Lam C., et al. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica-immunoglobulin G binding to aquaporin-4. The Journal of Biological Chemistry 2012, 287:36837-36844.
94. Phuan P.W., Ratelade J., Rossi A., Tradtrantip L., Verkman A.S. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. The Journal of Biological Chemistry 2012, 287:13829-13839.
95. Pisani F., Mastrototaro M., Rossi A., Nicchia G.P., Tortorella C., Ruggieri M., et al. Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. The Journal of Biological Chemistry 2011, 286:9216-9224.
96. Ponomarev E.D., Shriver L.P., Maresz K., Pedras-Vasconcelos J., Verthelyi D., Dittel B.N. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. Journal of Immunology 2007, 178:39-48.
97. Popescu B.F., Lennon V.A., Parisi J.E., Howe C.L., Weigand S.D., Cabrera-Gomez J.A., et al. Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications. Neurology 2011, 76:1229-1237.
98. Quan C., Yu H., Qiao J., Xiao B., Zhao G., Wu Z., et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: Distinct from multiple sclerosis. Multiple Sclerosis 2013, 19:289-298.
99. Ratelade J., Bennett J.L., Verkman A.S. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. The Journal of Biological Chemistry 2011, 286:45156-45164.
100. Ratelade J., Verkman A.S. Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. The International Journal of Biochemistry & Cell Biology 2012, 44:1519-1530.
101. Ratelade J., Zhang H., Saadoun S., Bennett J.L., Papadopoulos M.C., Verkman A.S. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathologica 2012, 123:861-872.
102. Ren Z., Wang Y., Duan T., Patel J., Liggett T., Loda E., et al. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: Potential relevance to neuromyelitis optica. Journal of Immunology 2012, 189:4602-4611.
103. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nature Biotechnology 2007, 25:1265-1275.
104. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
105. Rossi A., Ratelade J., Papadopoulos M.C., Bennett J.L., Verkman A.S. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E1511. author reply E2.
106. Rumbley C.A., Sugaya H., Zekavat S.A., El Refaei M., Perrin P.J., Phillips S.M. Activated eosinophils are the major source of Th2-associated cytokines in the schistosome granuloma. Journal of Immunology 1999, 162:1003-1009.
107. Saadoun S., Bridges L.R., Verkman A.S., Papadopoulos M.C. Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. Neuroreport 2012, 23:1044-1047.
108. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
109. Saadoun S., Waters P., MacDonald C., Bell B.A., Vincent A., Verkman A.S., et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Annals of Neurology 2012, 71:323-333.
110. Segal A.W. How neutrophils kill microbes. Annual Review of Immunology 2005, 23:197-223.
111. Serhan C.N. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual Review of Immunology 2007, 25:101-137.
112. Serhan C.N., Savill J. Resolution of inflammation: The beginning programs the end. Nature Immunology 2005, 6:1191-1197.
113. Shapira S.K., Jabara H.H., Thienes C.P., Ahern D.J., Vercelli D., Gould H.J., et al. Deletional switch recombination occurs in interleukin-4-induced isotype switching to IgE expression by human B cells. Heilkunde - Heilwege 1991, 88:7528-7532.
114. Sinclair C., Kirk J., Herron B., Fitzgerald U., McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathologica, Berlin 2007, 113:187-194.
115. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994, 76:301-314.
116. Strauss G., Vignali D.A., Schonrich G., Hammerling G.J. Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics 1994, 40:104-108.
117. Sturfelt G., Sjoholm A.G. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. International Archives of Allergy and Applied Immunology 1984, 75:75-83.
118. Sturfelt G., Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nature Reviews. Rheumatology 2012, 8:458-468.
119. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007, 130:1235-1243.
120. Tradtrantip L., Asavapanumas N., Verkman A.S. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an igg-Selective proteinase. Molecular Pharmacology 2013, 83:1268-1275.
121. Tradtrantip L., Ratelade J., Zhang H., Verkman A.S. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Annals of Neurology 2013, 73:77-85.
122. Tradtrantip L., Zhang H., Anderson M.O., Saadoun S., Phuan P.W., Papadopoulos M.C., et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB Journal 2012, 26:2197-2208.
123. Tradtrantip L., Zhang H., Saadoun S., Phuan P.W., Lam C., Papadopoulos M.C., et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology 2012, 71:314-322.
124. Uzawa A., Mori M., Arai K., Sato Y., Hayakawa S., Masuda S., et al. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Multiple Sclerosis 2010, 16:1443-1452.
125. Uzawa A., Mori M., Ito M., Uchida T., Hayakawa S., Masuda S., et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. Journal of Neurology 2009, 256:2082-2084.
126. Vaknin-Dembinsky A., Brill L., Kassis I., Petrou P., Ovadia H., Ben-Hur T., et al. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 2012, 79:945-946.
127. Vaknin-Dembinsky A., Brill L., Orpaz N., Abramsky O., Karussis D. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Multiple Sclerosis 2010, 16:1453-1457.
128. Varrin-Doyer M., Spencer C.M., Schulze-Topphoff U., Nelson P.A., Stroud R.M., Cree B.A., et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Annals of Neurology 2012, 72:53-64.
129. Varrin-Doyer M., Vincent P., Cavagna S., Auvergnon N., Noraz N., Rogemond V., et al. Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration. The Journal of Biological Chemistry 2009, 284:13265-13276.
130. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. Journal of Immunology 2008, 181:5730-5737.
131. Wang H.H., Dai Y.Q., Qiu W., Lu Z.Q., Peng F.H., Wang Y.G., et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. Journal of Clinical Neuroscience 2011, 18:1313-1317.
132. Wang H., Zhong X., Wang K., Qiu W., Li J., Dai Y., et al. Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese-A case control study. Journal of the Neurological Sciences 2012, 314:26-28.
133. Watanabe S., Nakashima I., Misu T., Miyazawa I., Shiga Y., Fujihara K., et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple Sclerosis 2007, 13:128-132.
134. Watanabe S., Nakashima I., Miyazawa I., Misu T., Shiga Y., Nakagawa Y., et al. Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange. Journal of Neurology 2007, 254:670-671.
135. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Archives of Neurology 2008, 65:913-919.
136. Weber M.S., Prod'homme T., Patarroyo J.C., Molnarfi N., Karnezis T., Lehmann-Horn K., et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Annals of Neurology 2010, 68:369-383.
137. Weinshenker B.G., Wingerchuk D.M., Vukusic S., Linbo L., Pittock S.J., Lucchinetti C.F., et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology 2006, 59:566-569.
138. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
139. Yu X., Green M., Gilden D., Lam C., Bautista K., Bennett J.L. Identification of peptide targets in neuromyelitis optica. Journal of Neuroimmunology 2011, 236:65-71.
140. Zadura A.F., Theander E., Blom A.M., Trouw L.A. Complement inhibitor C4b-binding protein in primary Sjogren's syndrome and its association with other disease markers. Scandinavian Journal of Immunology 2009, 69:374-380.
141. Zephir H., Fajardy I., Outteryck O., Blanc F., Roger N., Fleury M., et al. Is neuromyelitis optica associated with human leukocyte antigen?. Multiple Sclerosis 2009, 15:571-579.
142. Zhang H., Bennett J.L., Verkman A.S. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Annals of Neurology 2011, 70:943-954.
143. Zhang H., Ratelade J., Verkman A.S. Eosinophil pathogenicity in neuromyelitis optica by ADCC and CDCC mechanisms: Potential therapeutic efficacy of over-the-counter eosinophil stabilizing drugs 2012.
144. Zhang H., Verkman A.S. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. The Journal of Clinical Investigation 2013, 123:2306-2316.